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Abstract 
Metal-organic frameworks (MOFs), network structures wherein metal ions or clusters link 
organic ligands into porous materials, are being actively researched as nanoscale drug 
delivery devices (DDSs) as they offer tuneable structures with high cargo loading that can 
easily be further functionalized for targeting and enhanced physiological stability. The 
excellent biocompatibility of Zr has meant that its MOFs are amongst the most studied to 
date, in particular the archetypal Zr terephthalate UiO-66. In contrast, the isoreticular 
analogue linked by fumarate (Zr-fum) has received little attention, despite the endogenous 
linker being part of the Krebs cycle. Herein, we report a comprehensive study of Zr-fum in 
the context of drug delivery. Reducing particle size is shown to increase uptake by cancer 
cells while reducing internalisation by macrophages, immune system cells that remove 
foreign objects from the bloodstream. Zr-fum is compatible with defect-loading of the drug 
dichloroacetate, as well as surface modification during synthesis, through coordination 
modulation, and postsynthetically. DCA-loaded, PEGylated Zr-fum shows selective in vitro 
cytotoxicity towards HeLa and MCF-7 cancer cells, likely as a consequence of its enhanced 
caveolae-mediated endocytosis compared to uncoated precursors, and it is well tolerated by 
HEK293 kidney cells, J774 macrophages, and human peripheral blood lymphocytes. 
Compared to UiO-66, Zr-fum is more efficient at transporting the drug mimic calcein into 
HeLa cells, and DCA-loaded, PEGylated Zr-fum is more effective at reducing HeLa and 
MCF-7 cell proliferation than the analogous UiO-66 sample. In vitro examination of immune 
system response shows Zr-fum samples induce less reactive oxygen species than UiO-66 
analogues, possibly as a consequence of the linker being endogenous, and do not activate 
the C3 and C4 complement cascade pathways, suggesting that Zr-fum can avoid phagocytic 
activation. The results show that Zr-fum is an attractive alternative to UiO-66 for nanoscale 
drug delivery, and that a wide range of in vitro experiments are available to greatly inform the 
design of DDSs prior to early stage animal studies. 
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Introduction  
The requirement for new cancer treatments is driven by increases in the diagnosed cases of 
cancer, the side effects of most available therapeutics, and the resistance of some tumours 
towards them.1-3 Interest in drug delivery systems (DDSs) is increasing, with the ultimate aim 
of selectively targeting cancer cells with nanoscale “Trojan horses” capable of delivering 
therapeutic cargo directly to sites of disease.4-5 However, clinical application of DDSs faces 
drawbacks such as poor drug loading capacity,6 fast drug release kinetics,7 aggregation in 
the bloodstream,8 non-specific biodistribution or accumulation in the body9 and, in some 
cases, toxicity.10 Developing model DDSs and methodology for their surface modifications, 
with the aims of controlling their physical properties and understanding the correlation 
between the former and their therapeutic activity, is of vital importance to ultimately lead to 
the design of novel DDSs.11 Among these drug delivery devices, metal-organic frameworks 
(MOFs)12-13 – a new generation of highly porous, crystalline structures comprised of organic 
and inorganic components – have emerged as an alternative to combine the most attractive 
properties of organic (biocompatibility, targeted bio-distribution)14-15 and inorganic (high drug 
loadings, biostability)16-17 DDSs, making MOFs highly promising candidates to overcome the 
problems that nanomedicine is currently facing.18-20 
Zirconium-based MOFs have recently acquired significant interest as potential DDSs, as 
they are generally more thermally, mechanically and chemically stable than other MOF 
systems but will still degrade slowly under physiological conditions,21-22 while at the same 
time Zr has good biocompatibility23 and they are amenable to postsynthetic modification.24 
For example, the Zr terephthalate MOF UiO-66,25 where UiO stands for University of Oslo, 
and other MOFs of the UiO isoreticular series with ideal formula [Zr6O4(OH)4L6]n,
26 have 
been postsynthetically modified with a number of surface moieties, including poly-N-
isopropylacrylamide (PNIPAM),27-28 poly(ethylene glycol) (PEG),29 DNA sequences,30-31 small 
interfering RNA (siRNA),32 phospholipid bilayers,33 L-dopamine,34 and anticancer targeting 
units35 among others. Surface coatings have been proven to improve simulated physiological 
stability, colloidal dispersion and drug release kinetics, among other properties. 
While UiO-66 and the more porous MOFs of the UiO-66 series of MOFs have received 
widespread attention as potential DDSs,26, 36 application of the isoreticular MOF composed of 
the endogenous fumarate linker are rare.37 So-called Zr-fum (Figure 1) has a similar 
structure to UiO-66, but its porosity is reduced compared to the rest of the series (SBET ~800 
m2g-1) as the fumarate linker, an intermediate of the Krebs cycle, is shorter in length.38 Zr-
fum can be synthesised in water,38-39 and has requisite stability for application in water 
adsorption40 and harvesting,41 catalysis,42 and aqueous fluoride sequestration.43 
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Figure 1. Schematic showing the Zr-fum structure with preferred properties of a MOF-based drug 
delivery device. 
The potential application of Zr-fum nanoparticles of 83 ± 14 nm size as a DDS has been 
studied by Lachet and co-workers,37 by coordinating various pro-apoptotic peptides and a 
cytochrome c protein (CytC) to the external surface of the MOF using the imidazole groups 
of terminal oligohistidine residues (His-tags). The coating was proven to be stable at pH 7.4 
in HEPES buffered glucose (HBG), while partially released at pH 5, and completely cleaved 
at pH 3. Between 20 and 30 fold-increases in the internalisation of the various peptides by 
HeLa cervical cancer cells when attached to Zr-fum were observed; increases in cytotoxicity 
towards HeLa cells occur when pro-apoptotic peptides are delivered by the MOF, whereas 
free peptides are not cytotoxic as they cannot efficiently enter the cell. Additionally, the dye 
resorufin has been postsynthetically encapsulated in Zr-fum nanoparticles, followed by 
coating with galactosylamine, and used for intracellular imaging with no appreciable in vitro 
cytotoxicity towards FL83B and HepG2 cells.44 These promising results demonstrate the 
requirement for a systematic study into the functionalization, stability, degradation, and 
cytotoxicity of Zr-fum to assess its general performance as a DDS in vitro.  
The coordination modulation process,45 in which monodentate ligands (modulators) are 
introduced to MOF syntheses and compete with the multidentate linkers for the metal 
coordination sites, has been widely used to control the particle size of MOFs46-47 and to 
enhance their physical properties, such as crystallinity and porosity.48 The addition of 
modulators to synthesis of Zr MOFs is known to induce defects, such as missing clusters 
and linkers, and also install functionality on particle outer surfaces.28, 49-50 This process has 
been widely studied for UiO-66, and modulator incorporation has been found to be pKa 
dependent.51 While modulation is known to control the particle size of Zr-fum,38-39 the MOF 
has not received special attention for defect engineering.  
We have recently exploited this phenomenon to load an anticancer metabolic target, 
dichloroacetic acid (DCA), at defect sites within the bulk of Zr MOFs of the UiO-66 family 
during synthesis.49 These defects enhance their porosity, which can be used to store a 
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second anticancer drug, 5-fluorouracil (5-FU), resulting in dual drug loaded MOFs. The low 
pKa of DCA, together with its small size, ensures high incorporation (ca. 20% w/w) even in 
the presence of other modulators.28-29 Incorporation of both the cancer targeting folic acid 
(FA), and functionalised modulators, such as p-azidomethylbenzoic acid (L1), which can be 
further transformed by click chemistry, allow the assembly of surface functionalised, drug 
loaded UiO-66 nanoparticles which exhibit selective anticancer cytotoxicity. 
Herein, we extend these surface functionalization protocols to Zr-fum, aiming to develop 
protocols for the control of (i) particle size, in order to study the size dependence of Zr 
fumarate on its physical properties (i.e. colloidal dispersion and phosphate stability) and on 
its cellular uptake by cancer cells and macrophages, and (ii) surface chemistry, to find any 
correlation with physical properties and in vitro performance, with the ultimate aim of 
assessing the potential for in vivo application of Zr-fum.  
Results and discussion 
Particle Size Control. The cellular internalisation pathways by which nanoparticulate DDSs 
are internalised are size dependent.52-55 Nano-devices are often internalised by eukaryotic 
cells through active transport such as endocytosis, although if small enough (<20 nm) DDSs 
can be internalised by passive diffusion. Among endocytosis pathways, the most studied are 
receptor-mediated endocytosis (i.e. caveolae or clathrin-mediated),55 non-mediated 
endocytosis, and macropinocytosis.56 It has been reported that DDSs internalised through 
the caveolae-mediated route could be more successful in delivering their cargo into the 
cytosol, due to endosomal escape through DDS encapsulation in caveosomes.57 
Macrophages, the cells responsible for removing foreign bodies from the blood current, 
usually internalise matter through phagocytosis.58 
To study how size affects the internalisation of Zr-fum by cancer cells and macrophages, 
crystalline (Figure 2a) nanoparticles of different sizes were synthesised utilising two different 
metal precursors, ZrCl4 and ZrOCl2·8H2O, with acetic acid as a modulator (See SI, Section 
S2). The large sample, Zr-fum (b), where b stands for big, is 168 ± 24 nm in diameter, as 
determined by SEM (Figure 2b), while Zr-fum (s), where s stands for small, is 23 ± 11 nm in 
size (Figure 2c), explaining the broadening of reflections in its powder X-ray diffraction 
(PXRD) pattern. Full characterisation (SI, Section S4.1) – including FTIR spectroscopy, 
thermogravimetric analysis (TGA) and N2 adsorption and desorption isotherms – confirmed 
the samples to be thermally stable and porous (SBET = 865 m
2g-1 and 596 m2g-1 for Zr-fum (s) 
and Zr-fum (b) respectively). The pore volume of Zr-fum (s) at 0.98 p/p0 (0.978 cm
3g-1) 
compared to Zr-fum (b) (0.364 cm3g-1) suggests a high degree of defectivity, although it is 
possible this is filling of interparticle space between the very small nanoparticles.  
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Dynamic light scattering (DLS) measurements were performed in water (Figure 2d). Zr-fum 
(s) displays aggregates of size approximately 75 nm, while Zr-fum (b) forms aggregates of 
around 300 nm. This small amount of aggregation is in good agreement with the previous 
report from Lachelt and co-workers,37 where nanoparticles of 83 ± 14 nm (SEM) showed 
aggregation in DLS measurements to 132 nm (ethanol) and 182 nm (water).  
 
Figure 2. a) Stacked PXRD patterns for the Zr-fum samples compared to that calculated from its 
single crystal structure (CCDC ref code BOHJOZ).
40
 SEM images of b) Zr-fum (b) and c) Zr-fum (s) at 
different magnifications. d) Particle size distributions of the samples dispersed in water as measured 
by DLS. e) Degradation profiles in PBS 10X (pH 7.4) for the two samples as measured by UV/Vis 
spectroscopic determination of fumarate release. 
The stability of the samples in PBS 10X (pH = 7.4) was investigated through UV-Vis 
spectroscopic determination of fumarate release, showing the smaller sample to be initially 
more stable, but reaching similar levels of linker release after 24 h (Figure 2e). While Zr-fum 
(b) degrades with an exponential profile, reaching a plateau of 58% linker release after 8 h, 
the smaller analogue degrades with a two-step profile, with a slower rate during the first 3 h 
(releasing 20% vs 45% for the bigger analogue). Interestingly, Zr-fum seems to be more 
stable towards phosphate-induced degradation than UiO-66, which releases ~80% of its 
linker after a few hours.28 This is possibly a consequence of the lower pKa of fumaric acid 
compared to terephthalic acid resulting in a more stable metal-carboxylate bond, and thus 
enhancing the competition between free phosphates and carboxylates for the coordination to 
the Zr clusters. 
To monitor cellular uptake, a carboxylate containing fluorescent molecule, calcein, was 
postsynthetically loaded into the samples. Calcein is not able to efficiently cross the cell 
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membrane due to its hydrophilicity (logP = -4),59 and so it is an excellent probe for the 
cellular internalisation of MOFs.60 Calcein loading in cal@Zr-fum (s) was considerably higher 
(16.8% w/w) than for cal@Zr-fum (b) (3.4% w/w), presumably as a consequence of thes 
higher degree of defects and greater external surface-to-bulk ratio of the former compared to 
the latter. It has been previously reported for UiO-66 that, due to the size of calcein, the 
molecule is not able to efficiently penetrate the porosity of the MOF, and so it is most likely to 
be coordinated to Zr clusters at the outer surface and at defect sites through its carboxylate 
groups.29 Zr-fum has a smaller pore window than UiO-66;25, 38 TGA and FTIR measurements 
confirm that external surface loading also occurs for Zr-fum (SI, Section S4.2.). 
Fluorescence assisted cell sorting (FACS) was used to monitor the cellular internalisation of 
the cal@MOFs (SI, Section S3), showing that the smaller cal@Zr-fum (s) was more 
efficiently internalised by HeLa cervical cancer cells (by a factor of 2.3), while cal@Zr-fum 
(b) was better internalised by J774 macrophages (by a factor of 1.6) (Figure 3a). Importantly, 
cal@Zr-fum (s) was able to deliver calcein into HeLa cells with a 20-fold increase compared 
to free calcein, which is considerably higher than previously found for cal@UiO-66 (5-10 fold 
increase).28, 61 The use of inhibitors of certain endocytic pathways28 – chlorpromazine and 
sucrose for clathrin-mediated endocytosis (although sucrose also inhibits non-mediated 
pathways), nystatin for caveolae-mediated endocytosis, and rottlerin for macropinocytosis – 
enables an assessment of the effect of particle size on the major routes of internalisation of 
Zr-fum by HeLa cancer cells when compared to uninhibited cellular uptake (Figure 3b). 
Lachet’s previous study of internalisation routes involved Zr-fum nanoparticles37 (surface 
modified with a fluorescent peptide) of size ~ 83 nm, an intermediate size compared to the 
MOFs here presented (~25 nm and ~170 nm). The surface modified MOF was partially 
internalised through the caveolae-mediated route, with minor contribution of 
macropinocytosis. Zr-fum (b) was internalised primarily through macropinocytosis (~44 ± 5% 
inhibition by rottlerin), showing only a minor contribution of clathrin-mediated endocytosis. 
This pathway plays a more important role in the internalisation of Zr-fum (s) (~31 ± 2% 
inhibition by chlorpromazine), whereas macropinocytosis does not play a significant role for 
the smaller MOF. Inhibition of the caveolae-mediated pathway does not alter the cellular 
internalisation of either of the MOFs, indicating that uptake by HeLa cells does not occur 
through the caveolae-mediated pathway. It is likely the caveolae-mediated uptake observed 
by Lachet37 is induced by the peptides attached to the surfaces of their Zr-fum sample, and 
we have observed a similar effect when coating UiO-66 with poly(ethylene glycol) (PEG) 
chains.29 
To assess the contribution of non-active transport (i.e. passive diffusion) a control in which 
the cells were incubated with the MOFs at 4 ºC, a temperature at which most cellular 
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functions are attenuated,62 was performed and normalised to the cellular internalisation at 37 
ºC (Figure 3b). The higher degree of internalisation of cal@Zr-fum (s) at 4 ºC (37 ± 1% vs 21 
± 1% for cal@Zr-fum (b)) indicates that passive diffusion could play some role in its cellular 
internalisation, although not to the same extent as active transport, which is of greater 
importance. Passive diffusion can also facilitate cytosolic localisation, which is favourable for 
drug delivery.63 
 
Figure 3. a) Endocytosis efficiencies of cal@Zr-fum (s) and cal@Zr-fum (b) towards HeLa and J774 
cells, compared to free calcein, and normalised to the values for cal@Zr-fum (s). b) Endocytosis 
efficiencies of the two samples towards HeLa cells in the presence of inhibitors for certain endocytic 
pathways. The statistical significance compared to the control was determined by ordinary one-way 
ANOVA and is indicated on the graph: *P<0.05; **P<0.01 ***P < 0.001 and ****P < 0.0001. 
Surface Functionalisation. Due to these encouraging results – particle size reduction 
resulting in an enhancement in internalisation cancer cells internalisation, with possible 
passive diffusion, and a decrease in macrophage recognition – cal@Zr-fum (s) was selected 
for further study. Surface modifications with folic acid (targeting)64 and PEG (dispersion, 
immune system avoidance)65 were attempted during synthesis and postsynthetically 
(Scheme 1), following our previously reported protocols (SI, Section S2).28-29 To maintain 
particle size, the surface of Zr-fum (s) was addressed with p-azidomethyl benzoic acid (L1) 
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and folic acid (FA) postsynthetically, using the surface ligand exchange (SLE) protocol, to 
yield Zr-fum-L1 (s) and Zr-fum-FA (PS), respectively, where PS stands for postsynthetic. The 
azide functionality of L1 was subsequently used to covalently attach propargyl-terminated 
PEG2000 chains to the outer surface of the MOF through copper-catalysed azide-alkyne 
cycloaddition (CuAAC), to form Zr-fum-L1-PEG2000 (s). Additionally, Zr-fum-FA (CM) was 
prepared through co-modulation with folic acid and acetic acid, where CM stands for 
coordination modulation, in order to study the effect of coating protocol on the colloidal 
dispersion and stability towards phosphate attack. 
Scheme 1. Synthetic scheme for the synthesis of surface-functionalised Zr-fum samples. 
 
Full characterisation of the samples (SI, Section S5) confirms the incorporation of the 
surface functionalities, with retention of crystallinity confirmed by PXRD. 1H NMR spectra of 
acid digested samples contain characteristic resonances for protons of L1 and folic acid, with 
a content of ca. 19 mol % and 17 mol %, both compared to fumarate, for L1 and folate, 
respectively. The azide functionality of L1 was identified in the FT-IR spectrum of Zr-fum-L1 
(s), while the carboxylate band of folic acid is shifted in the FT-IR spectra of both Zr-fum-FA 
(PS) and Zr-fum-FA (CM) as a consequence of folate attachment to the available Zr clusters. 
Vibration bands characteristic of the PEG moieties are also observed in the FT-IR spectrum 
of Zr-fum-L1-PEG2000 (s), while disappearance of the azide band is a consequence of the 
CuAAC reaction and consequent covalent attachment. TGA profiles showed similar features 
to those of previously reported analogous UiO-66 samples;28-29 a decrease in residual ZrO2 
content of all samples, more gradual decomposition profiles for the folate-coated samples, 
and earlier structure decomposition upon PEGylation. A decrease in porosity was also 
observed for the postsynthetically coated samples (SBET = 504 m
2g-1, 628 m2g-1, and 570 
m2g-1 for Zr-fum-FA (PS), Zr-fum-L1 (s), and Zr-fum-L1-PEG2000 (s), in turn) in great 
agreement with surface reagent incorporation, whereas Zr-fum-FA (CM) was highly porous 
(SBET = 821 m
2g-1) as a consequence of the induction of defects through folate attachment 
during synthesis. 
Although the aggregation of Zr-fum (s) in water was not remarkable (~75 nm), its colloidal 
stability was slightly improved upon PEGylation (~70 nm), and to a higher extent upon folate 
coating (~50 nm) (Figure 4a). The sample prepared through coordination modulation, Zr-
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fum-FA (CM), displayed aggregates of ~250 nm, close to the size determined by SEM (~170 
nm). The degradation of the samples was measured in PBS 10X (pH 7.4) (Figure 4b). An 
induction period, more pronounced than for the precursor Zr-fum (s), was observed upon 
PEGylation, in which Zr-fum-L1-PEG2000 (s) only releases <5% of the fumarate linker 
during the first hour, although subsequently degrading with a similar profile, within error, to 
its precursor after 1.5 h, possibly as a consequence of detachment of the PEG corona. In 
contrast, Zr-fum-FA (PS) degraded faster than its precursor, whereas the folate-modulated 
sample Zr-fum-FA (CM) was remarkably more stable than the bare MOF, with an induction 
time similar to the postsynthetically PEGylated sample and a slower degradation rate, 
reaching a plateau of 20% linker release after 6 h of degradation and not releasing any 
further linker after 25 h. These results indicate that the nature of the coating plays an 
important role during the samples degradation.  
 
Figure 4. a) Particle size distributions of the Zr-fum samples in water measured by DLS. b) 
Degradation profiles in PBS 10X (pH 7.4) of the Zr-fum samples measured by UV/Vis determination of 
fumarate release, with the inset showing the induction period of prolonged stability for the PEGylated 
sample compared to the uncoated one. 
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In order to study the effect of surface coating on cellular internalisation of the MOFs, calcein 
was loaded into Zr-fum (s) and Zr-fum-L1 (s), to yield cal@Zr-fum (s) and cal@Zr-fum-L1 (s), 
respectively (Scheme 2). The former was postsynthetically coordinatively coated with folic 
acid, while the latter was PEGylated covalently by CuAAC, using the same postsynthetic 
modification protocols as previously. Full characterisation (SI Section S5.2) confirmed the 
attachment of the surface reagents to the surface of cal@Zr-fum (s). 
Scheme 2. Synthetic methodology for preparing calcein loaded Zr-fum samples. 
 
The efficacy of internalisation of the MOFs by HeLa and J774 macrophage cells was 
assessed by FACS (Figure 5a). Coating the surface of Zr-fum (s) with L1 did not significantly 
alter HeLa internalisation, whereas PEGylation decreased cell internalisation by 42 ± 2%, 
possibly as a consequence of the more neutral surface. Folate coating increased the MOF 
internalisation by 58 ± 5% compared to the bare MOF, possibly as a consequence of the 
overexpression of folate receptors on the surface of HeLa cervical cancer cells.66 J774 
macrophage internalisation was also investigated, showing a slight increase in uptake upon 
PEGylation (134 ± 12%) and a non-significant increase after folate coating (114 ± 12%) 
compared to the non-coated sample cal@Zr-fum (s) (100 ± 5%). Of all the samples studied, 
cal@Zr-fum (b) was still the most internalised MOF by macrophages, with 159 ± 8% 
internalisation compared to cal@Zr-fum (s) (Figure 3). 
Analysis of HeLa cell endocytosis routes of the samples was also performed. Incubation at 4 
ºC decreased cell internalisation of cal@Zr-fum-L1 (compared to incubation at 37 °C) to 
similar levels as its precursor cal@Zr-fum (s) (33 ± 3% uptake vs 37 ± 1%), whereas the 
effect was less pronounced for the PEGylated (62 ± 4% uptake) and folate-coated MOFs (79 
± 5% uptake), indicating a higher contribution of non-active transport (Figure 5b). It is 
important to consider that although the average particle size distribution of Zr-fum (s) (23 ± 
11 nm) is slightly above the size expected to allow passive diffusion through the cell 
membrane, a considerable portion of the nanoparticles is smaller than 20 nm (Figure S5), 
and so, after surface coating with more lipophilic moieties, the passive diffusion of this 
population of smaller nanoparticles could be enhanced.67 
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Figure 5. a) Endocytosis efficiencies of the surface-modified Zr-fum samples towards HeLa and J774 
cells, compared to free calcein, and normalised to the values for cal@Zr-fum (s) for each cell line. b) 
Endocytosis efficiencies of the samples towards HeLa cells in the presence of inhibitors for certain 
endocytic pathways. The statistical significance compared to controls was determined by ordinary 
one-way ANOVA and is indicated on the graph: *P<0.05; **P<0.01 ***P < 0.001 and ****P < 0.0001. 
The high degree of inhibition upon incubation with sucrose for all MOFs indicates non-
mediated transport contributes to their internalisation. Apart from a small decrease in the 
contribution of macropinocytosis and clathrin-mediated endocytosis, the routes of 
internalisation of cal@Zr-fum-L1 (s) did not vary significantly compared to the bare analogue 
(Figure 5b). Higher degrees of clathrin-mediated endocytosis participation were observed 
after surface modifications with folate and PEG, for which inhibition of 48 ± 3% and 52 ± 4% 
were respectively observed after incubation with chlorpromazine. A decrease in 
internalisation of cal@zr-fum-L1-PEG2000 (s) (~48 ± 2%) upon incubation with nystatin 
indicates significant contribution of the caveolae-mediated route, in good agreement with our 
previous work, where PEGylation induces caveolae-mediated HeLa cell uptake of cal@UiO-
66 (~150 nm).29 These results suggest that coating different MOFs with PEG chains can 
induce uptake through caveolae mediated-endocytosis, seemingly without a major size 
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effect. On the other hand, in contrast to cal@UiO-66-FA, which was determined to be 
partially internalised by caveolae-mediated endocytosis,28 the internalisation of cal@Zr-fum-
FA (s) was not inhibited by nystatin. This may be a consequence of passive diffusion still 
occurring in the presence of nystatin due to the small particle size, but this would also be 
expected to occur when the clathrin-mediated pathway is inhibited by chlorpromazine. 
Drug Delivery. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (PDK) 
inhibitor.68 Thus, DCA shifts cancer cell metabolism from glycolysis back to glucose 
oxidation by pyruvate dehydrogenase re-activation, unlocking cancer cells from a state of 
apoptosis resistance without affecting growth of healthy cells.69-70 However, the hydrophilic 
nature of DCA means it does not efficiently cross the cell membrane,71 resulting in limited 
ability to reach its target and rapid clearance from the bloodstream.72 Consequently, DCA 
has half maximum effective concentration (EC50) values in the millimolar range,
73 meaning 
that doses three orders of magnitude higher than for current anticancer drugs are needed to 
induce a similar therapeutic effect. Nevertheless, in vitro studies have shown remarkably 
lower resistance factors towards DCA compared to other anticancer therapeutics,73-74 and 
DCA has also been shown to enhance the anticancer effect of well-known drugs such as 5-
fluorouracil and cisplatin.73, 75-76 While DCA is not currently under clinical use as an 
anticancer drug, several clinical trials have shown that DCA treatment induces significant 
tumour remission with very low side effects and toxicity compared to other therapeutics.77-80 
DCA’s excellent therapeutic activity combined with its poor cellular internalisation makes it a 
highly informative mechanistic probe to study the potential effect of MOFs as DDSs, as a 
substantially enhanced cytotoxicity will be a consequence of efficient internalisation of the 
MOFs and the subsequent release of their cargo into the cytosol. 
In order to study the effect of particle size and surface chemistry on therapeutic activity, 
dichloroacetic acid was introduced as a modulator of Zr-fum synthesis, with or without the 
co-modulation of folic acid, to prepare DCA@Zr-fum (s) and DCA@Zr-fum-FA (CM), 
respectively (Scheme 3). 
Scheme 3. Synthetic scheme for DCA-loaded, surface modified Zr-fum samples. 
 
Figure 6 shows the typical analytical techniques used to monitor DCA incorporation into 
DCA@Zr-fum (s) (see SI Section S6 for full characterisation of other samples). DCA is an 
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effective modulator of Zr MOFs, with crystallinity retained but weak broad reflections 
indicating small particle size and/or defectivity (Figure 6a). As a consequence of the low pKa 
of DCA (~1.4), its incorporation into the MOFs at defect sites was considerable (~20% w/w). 
Loading can be assessed by thermogravimetric analysis (TGA, Figure 6b) so long as its 
thermal decomposition does not overlap with surface functionality, and confirmed by ICP-MS 
analysis of Cl content (20.4% w/w for DCA@Zr-fum (s)). FT-IR spectra (Figure 6c) also 
showed its presence within the MOF samples, with a shifting of the DCA carbonyl stretch 
from ca. 1730 cm-1 to 1650 cm-1 indicating its coordination to the Zr clusters. The particle 
size distributions, determined by SEM (Figures S43-S46), highlight the role of the 
modulators during the crystallisation process. DCA@Zr-fum (s) has a homogenous size 
distribution profile composed of nanoparticles with an average size of 28 ± 9 nm, whereas 
the particle size increases noticeably for DCA@Zr-fum-FA (CM), with size distribution 
profiles of ca. 99 ± 19 nm, while both samples are relatively well dispersed in water, with 
average sizes of ~75 and ~ 250 nm, respectively. The folate content of DCA@Zr-fum-FA 
(CM) was determined by UV-Vis spectroscopy of digested samples and found to be 
significant (17.9% w/w) indicating incorporation in the bulk as well as at the outer surfaces. 
DCA loading could be measured by ICP-MS and was found to be 19.5% w/w. N2 adsorption 
and desorption measurements proved the samples to be porous despite the high DCA and 
folate content, with SBET = 622 m
2g-1 and 482 m2g-1 for DCA@Zr-fum (s) and DCA@Zr-fum-
FA (CM) respectively, with the lower porosity of the latter indicative of significant 
incorporation of folate. 
 
Figure 6. Comparison of DCA@Zr-fum (s) with Zr-fum (s). a) Partial stacked PXRD patterns showing 
retention of crystallinity on DCA loading. b) TGA traces showing DCA degradation around 250-350 
°C. c) Stacked IR spectra showing the presence of DCA and the shifting of the carbonyl stretch of 
DCA when coordinated to Zr-fum. 
Zr-fum-L1 (s) was postsynthetically loaded with DCA (Scheme 3) by stirring in a methanolic 
solution containing DCA (10% v/v) and L1 (1 mgmL-1), to ensure that DCA attachment to the 
Zr positions will not result in the displacement of L1, as the pKa of DCA is considerably lower 
than for benzoic acid derivatives. 1H NMR spectra of acid-digested DCA@Zr-fum-L1 (s) 
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confirmed the presence of both L1 (~7 mol % compared to fumarate) and DCA (~40 mol %). 
DCA loading was also calculated by ICP-MS and TGA, with both techniques confirming 
approximately 20% w/w loading (ICP-MS: 21.1% w/w). The azide functionality of L1 was 
subsequently reacted with propargyl-terminated PEG2000 by CuAAC, leading to DCA@Zr-
fum-L1-PEG2000 (s). The thermal decomposition of DCA and PEG occur at similar 
temperatures, resulting in an overall structure decomposition and hindering DCA 
determination by TGA in the PEGylated sample (Figure S53). The DCA loading of 12.1% 
w/w, determined by ICP-MS, is lower than the precursor – a consequence of the extra 
addition of mass through the PEG chains and possible detachment of some of the DCA 
under reaction conditions (acetic acid is used as a co-ligand for the Cu(I) catalyst). DLS 
showed the sample had a similar minor degree of aggregation in water to its precursor.  
For comparison. the biocompatibility of the bare and surface-modified samples without cargo 
– Zr-fum (s), Zr-fum-FA (PS) and Zr-fum-L1-PEG2000 (s) was investigated by incubation 
with HeLa cervical cancer cells (Figure S60), showing >100% proliferation compared to 
controls after incubation with 1 mgmL-1 of the MOFs for 72 h, as determined by the MTS 
assay. Increased proliferation could be a consequence of cellular metabolisation of the 
endogenous fumarate linker. Incubation of HeLa cancer cells (Figure 7a) with DCA@Zr-fum 
(s) and DCA@Zr-fum-FA (CM) for 72 h did not affect HeLa cell proliferation, whereas 
DCA@Zr-fum-L1-PEG2000 (s) was highly cytotoxic at concentrations of 0.5 mgmL-1 after 24 
h. The cytotoxicity of the PEGylated sample is possibly a consequence of its partial 
internalisation through caveolae-mediated endocytosis,57 while it is significantly more 
cytotoxic towards HeLa than its UiO-66 analogue,29 suggesting that Zr-fum is more effective 
at delivering DCA into the cells. It is important to take into account that although DCA@Zr-
fum (s) has a particle size distribution (29 ± 9 nm) similar to Zr-fum (s) (23 ± 11 nm), the 
fraction of nanoparticles smaller than 20 nm is less significant, as can be observed in the 
particle size distribution histograms (Figure S46), meaning that passive diffusion may be less 
prevalent for this sample. DCA@Zr-fum-FA (CM) is bigger in size (ca. 100 nm), comparable 
to cal@Zr-fum (b), which was proven not to be internalised significantly by HeLa cells 
compared to the smaller analogues. Additionally, folate-coated cal@Zr-fum-FA (PS) did not 
show any significant caveolae-mediated uptake, which seems to be key to efficient DCA 
cytotoxicity. The PEGylated MOF has the lowest DCA loading (12.1% w/w), thus enhancing 
the therapeutic effect of the free drug by a factor of over 20028 and highlighting the 
importance of the endocytosis routes of the DDSs on therapeutic efficacy.  
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Figure 7. Cytotoxicity of DCA-loaded Zr-fum samples measured by MTS assay towards a) HeLa cells 
over 24 and 72 h incubation, and b) MCF-7 and HEK293 cells for 72 h. Cytotoxicity of empty and 
DCA-loaded Zr-fum samples measured by MTT assay towards c) J774 macrophage cells and d) 
peripheral blood lymphocytes isolated from human donors. Plots of cytotoxicity against DCA 
concentrations in the respective MOFs, with appropriate statistical analyses, are provided in the SI 
Section S7. 
The selectivity of cytotoxicity was investigated against MCF-7 human breast carcinoma and 
HEK293 human embryonic kidney cell lines (Figure 7b). DCA@Zr-fum (s) and DCA@Zr-
fum-FA (CM) have a moderate cytotoxic effect towards MCF-7 breast cancer cells (29 ± 8% 
and 36 ± 8% cell proliferation at 1 mgmL-1, respectively), whereas both MOFs were non-
cytotoxic towards HEK293 kidney cells (145 ± 8% and 186 ± 14% cell proliferation at 1 
mgmL-1, respectively). DCA@Zr-fum-L1-PEG2000 (s) has a similar cytotoxic effect towards 
MCF-7 cells (45 ± 10% and 44 ± 7% cell proliferation at 0.75 and 1 mgmL-1, respectively), 
however, its non-selective cytotoxicity towards HEK293 at higher concentrations – 145 ± 
43% cell proliferation at 0.75 mgmL-1 decreases rapidly to 48 ± 7% proliferation at 1 mgmL-1 
– might indicate potential problems towards in vivo application if significant accumulation is 
observed. A similar effect has been seen previously for DCA delivery with analogous 
PEGylated UiO-66 at the same dosage,28 and overall, DCA@Zr-fum-L1-PEG2000 (s) seems 
to be more efficient at enhancing the selective anticancer cytoxicity of DCA than its UiO-66 
analogue (SI, Figure S71).  
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Immune System Compatibility. In order to understand the possible effect of the MOFs 
towards cells of the immune system, such as macrophages and lymphocytes, the cell 
proliferation of J774 mouse macrophage cells and peripheral blood lymphocytes (PBLs) 
isolated from the blood of three human donors were investigated upon incubation with DCA-
containing and empty MOFs (SI, Section S3). Both the empty and the DCA-containing MOFs 
were non-cytotoxic (cell proliferation >90%) after incubation with 0.5 mgmL-1 of MOF for both 
J774 cells (Figure 7c) and PBLs (Figure 7d). The reactive oxygen species (ROS) production 
in macrophages induced upon incubation with MOFs is represented in Figure 8a. Incubation 
with DCA@Zr-fum (s) induced the highest increase in ROS production (~3-fold) followed by 
DCA@Zr-fum-FA (CM) (~2.5-fold) and their empty analogues (~1.5-fold), while incubation 
with the PEGylated samples did not induce ROS production compared to the untreated 
control, even if it was the most internalised MOF.  
 
Figure 8. a) Reactive oxygen species (ROS) generation in J774 macrophage cells on exposure to 
empty and DCA-loaded Zr-fum samples. Complement cascade activation in human blood plasma 
induced by incubation with empty and DCA-loaded Zr-fum samples, plotted for production of b) C3 
and c) C4 complement components, averaged from blood samples from three human donors. 
The complement cascade activation (C3 and C4) was investigated upon incubation of blood 
plasma from three human donors with the MOFs. The complement cascade is a part of the 
immune system which eliminates foreign pathogens, and its activation usually results in 
activation of phagocytic cells and inflammation.81 In Figures 8b and 8c, the data are 
represented as averages of the C3 and C4 concentrations, respectively, in serum of three 
different donors after treatment with different concentrations of the MOFs, normalised to a 
control in which blood plasma was treated with PBS. Individual data for each donor are given 
in the supporting information (Section S8), together with the hemolysis index upon treatment 
with each material. There was no significant difference from the control with PBS in any of 
the cases, meaning that the MOFs do not activate the complement cascade and so should 
be able to circulate in the blood without activation of phagocytes. 
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Conclusions 
In the context of nanoscale drug delivery, the UiO series MOF linked by the endogeneous 
fumarate ligand, Zr-fum, has been shown to be amenable to size-controlled synthesis and 
surface modification by a number of protocols. The anticancer probe molecule DCA has 
been introduced to Zr-fum as a modulator during synthesis, with payloads of 20% w/w stored 
at defect sites, and the samples could also be surface modified without major DCA leakage. 
Cellular internalisation of Zr-fum was found to be size dependent; the smaller sample, Zr-fum 
(s) (~23 nm) was significantly better internalised by HeLa cervical cancer cells compared to 
the bigger analogue Zr-fum (b) (~170 nm), yet the latter was more internalised by 
macrophages, suggesting liver and spleen accumulation could be reduced by effective size 
refinement through in vitro studies previous to in vivo trials. Additionally, the efficient 
internalisation of the smaller MOFs at 4 ºC indicates that passive diffusion could play an 
important role in cellular uptake. While PEGylation of Zr-fum can induce caveolae-mediated 
endocytosis, as has been found to be the case for UiO-66,29 folate coating in contrast does 
not result in caveolae-mediated uptake. PEGylation was proven to initially stabilise the 
MOFs towards phosphate attack on immersion in PBS, with an induction time with minimal 
degradation (< 5%) followed by similar degradation to the uncoated precursor MOF, possibly 
as a consequence of PEG corona cleavage. Additionally, postsynthetic surface modifications 
further improved the colloidal dispersion of the MOFs.  
Use of the endogenous fumarate linker was expected to enhance biocompatibility of the 
MOFs compared to UiO-66 and other derivatives. The MOFs (both empty and DCA-loaded) 
were non-toxic towards a series of non-cancerous cell lines, including J774 macrophages, 
HEK293 kidney cells and lymphocytes isolated from the blood of human donors; some 
residual cytotoxicity of DCA@Zr-fum-L1-PEG2000 (s) towards kidney cells at high 
concentrations was the only concern. Only the PEGylated DCA@Zr-fum-L1-PEG2000 (s) 
induced cytotoxicity towards HeLa cancer cells, stopping all proliferation when incubated at 
0.5 mgmL-1 (ca 0.06 mgmL-1 DCA) indicating that internalisation through the caveolae-
mediated route enhances the therapeutic effect of DCA by a factor of 200. All three DCA-
containing samples were cytotoxic towards MCF-7 breast cancer cells, with the PEGylated 
MOF once again the most effective for delivery of DCA, and more effective for delivery of 
DCA than its UiO-66 analogue. The composition of Zr-fum was also expected to mediate 
immune system response, in addition to the small size decreasing macrophage uptake. 
Surface modification did not notably change uptake of the MOFs by macrophage cells and 
had no effect on proliferation, while both empty and DCA-containing Zr-fum-L1-PEG2000 (s) 
did not induce significant ROS production; the bare sample induced the highest ROS 
production, with a 3-fold increase, which is less than observed for related UiO-66 
 19 
nanoparticles.28 Complement cascades (C3 and C4) in the blood plasma of three different 
human donors were not activated upon incubation with any of the empty or DCA-loaded 
MOFs, again showing good toleration of the nanoparticles by important immune system 
species.  
Taken together, the improvement in both selective in vitro anticancer cytotoxicity and 
immune system compatibility compared to UiO-66 suggest Zr-fum is an excellent candidate 
for further investigation as a drug delivery device, with fine control over particle size and 
functionality possible. Additionally, the study highlights the in vitro experimental toolkit 
available to allow tuning of a range of properties of DDSs without invoking animal studies. 
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